Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Dr. Helen Sabzevari est le President de Precigen Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action PGEN ?
Le prix actuel de PGEN est de $3.46, il a augmenté de 11.61% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Precigen Inc ?
Precigen Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Precigen Inc ?
La capitalisation boursière actuelle de Precigen Inc est de $1.2B
Est-ce que Precigen Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Precigen Inc, y compris 2 achat fort, 6 achat, 2 maintien, 0 vente et 2 vente forte